News | May 20, 2008

FDA Clears Calypso’s GPS for the Body for Prostatectomy Patients

May 21, 2008 - Calypso Medical said the FDA cleared a new indication for the use of implantable Beacon electromagnetic transponders with the Calypso System in external beam radiation therapy.

Known as GPS for the Body, the Calypso System utilizes transponders to setup and continuously track the position of targeted tissue during radiation treatment. In the event that the tumor site moves outside of acceptable limits, the clinician adapts therapy during daily treatment to ensure the treatment is delivered as prescribed to the cancerous tissue while avoiding adjacent healthy organs. This is reportedly the only technology platform designed to provide objective, accurate and continuous tracking information during external beam radiation therapy without adding ionizing radiation. Radiation therapy is the standard of care for patients with a high risk of prostate cancer recurrence or those in whom recurrence has been diagnosed.

Previously this technology was cleared solely for use in patients with an intact prostate. Studies indicate up to 20 percent of prostatectomy patients are diagnosed with recurrent prostate cancer following surgery and require adjuvant radiation therapy.

"Patients with high Gleason scores, extracapsular extension, positive surgical margins or seminal vesicle involvement are at risk of developing biochemical failure following radical prostatectomy,” said David I. Lee, M.D., a University of Pennsylvania urologist. “These patients often need adjuvant radiation therapy. Having the benefit of continuous real-time tracking during radiation therapy is critical to minimizing possible complications associated with external beam radiation therapy. It is imperative to know precisely where the prostatic bed is located during radiation treatment. The objective tracking data, provided by the Calypso System, may be the key to achieving the desired outcomes for these aggressive cases.”

For more information: www.calypsomedical.com

Related Content

Videos | Radiation Oncology | November 06, 2018
Genomics can be used to assess a patient's radiosensitivity, which can be used to increase or decrease the radiation
The Reflexion combination PET-CT linac, on display at ASTRO 2018. The system uses PET radiotracer emissions to track tumors directly without the need for margins to account for respiratory motion. #ASTRO18 #ASTRO2018 #ASTRO

The Reflexion combination PET-CT linac, on display at ASTRO 2018. The system uses PET radiotracer emissions to track tumors directly without the need for margins to account for respiratory motion. 

News | Radiation Therapy | October 30, 2018
October 30, 2018 - Displayed for the first time at ...
News | Radiation Dose Management | September 24, 2018
AngioDynamics Inc. announced an agreement to acquire RadiaDyne, a privately held medical diagnostic and device company...
Sponsored Content | Webinar | Radiation Therapy | August 28, 2018
Respiratory tumor motion often complicates the delivery of precision radiation treatment.
Magseed magnetic marker
Technology | Tumor Tracking Systems | July 20, 2018
Endomag, the surgical guidance company, received 510(k) clearance from the U.S.
​ITN Celebrates World Cancer Day 2018
News | Radiation Oncology | February 01, 2018
World Cancer Day takes place annually on Feb.
Study shows tissue marker reduces radiation target volumes, produces many other advantages

These CT images show placement of a 3-D fixed array implanted fiducial (3-D marker) at the time of oncoplastic tumor resection. The original LCTV (LCTVo) was retrospectively re-contoured by the radiation oncologist (LCTVro) and breast surgeon (LCTVbs). Thereafter, both re-contours were combined to create the collaborative LCTV (LCTVc), which required agreement of both the radiation oncologist and breast surgeon. Volume differences between the original LCTV (LCTVo) and the collaborative LCTVc were then evaluated, and demonstrated a mean and median reduction in LCTV.

Feature | Tumor Tracking Systems | November 06, 2017 | By William Hall, M.D.
Radiation planning for breast cancer relies on accurate delineation of the post-lumpectomy target volume as identified...
El Camino Hospital to Offer Calypso 4-D Localization System
News | Radiation Therapy | July 21, 2017
El Camino Hospital (Mountain View, Calif.) announced the installation of a new Calypso 4-D Localization System and will...
MR-HIFU, ThermoDox, combination therapy, recurrent childhood tumors, Celsion, Children's National Health System, Phase I clinical study
News | Oncology Related Products | December 19, 2016
December 19, 2016 — Children’s National Health System and Celsion Corp.
News | Clinical Decision Support | October 27, 2016
October 27, 2016 — The National Comprehensive Cancer Network (NCCN) continues to build its library of appropriate use